Application value of ST2 combined with CEA and CYFRA211 in diagnosis of early non-small cell lung cancer

• Published in: Zhenduanxue Lilun yu Shijian Vol. 22; no. 5; pp. 441 - 447
• Main Author: FAN Zhenjia, ZHAO Juntao, ZHOU Jiakuan, LI Zhanquan, WAN Yinglei
• Format: Journal Article
• Language: Chinese
• Published: Editorial Office of Journal of Diagnostics Concepts & Practice 01.10.2023
• Subjects: soluble growth stimulation gene 2 protein|non-small cell lung cancer|carcinoembryonic antigen|cytokeratin 19 fragment
• ISSN: 1671-2870
• DOI: 10.16150/j.1671-2870.2023.05.004

Objective: To explore soluble growth stimulation expressed gene 2 protein (ST2), carcinoembryonic antigen（CEA） and cytokeratin fragment 21-1 (CYFRA211) in diagnosing early non-small cell lung cancer (NSCLC). Methods: From January to August 2023, 91 patients with early NSCLC (TNM stage Ⅰ) and 21 patients with middle and advanced NSCLC [TNM stage Ⅱ (16 cases) and Ⅲ (5 cases)] admitted to Ruijin Hospital were collected, and 50 patients with benign lung lesions(BL) and 50 healthy people(HC) were served as controls. Plasma ST2 levels were detected by fluorescence immunochromatography, and serum CEA and CYFRA211 levels were detected by chemiluminescence. The differences between groups were compared, and the diagnostic value of index alone or in combination for NSCLC was analyzed. Results: ST2 level in the early NSCLC group was higher than that in the BL and HC group （P<0.001), and ST2 level in BL group was higher than HC group (P<0.001). The CEA level in the early NSCLC group were higher than that in the HC group (